Method of diagnosing an RTK-hyperfunction induced disorder

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S009100, C530S350000

Reexamination Certificate

active

08043806

ABSTRACT:
The invention provides method of diagnosing a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder or a genetic predisposition therefor in a mammal. The method comprises determining the presence of a nucleic acid encoding a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample from a mammal. The presence of a nucleic acid encoding a mutated FGFR-4 protein is indicative of an RTK-hyperfunction-induced disorder or a genetic predisposition therefor.

REFERENCES:
patent: 4988617 (1991-01-01), Landegren et al.
patent: 6770742 (2004-08-01), Ullrich et al.
patent: 7297774 (2007-11-01), Ullrich et al.
patent: WO 92/13948 (1992-08-01), None
patent: WO 95/21938 (1995-08-01), None
patent: WO 96/31605 (1996-10-01), None
patent: WO 96/36641 (1996-11-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 98/24432 (1998-06-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 99/37299 (1999-07-01), None
Gaudenz et al. 1998. Mol. Genetics and Metab. 64:76-79.
Armstrong et al., “Expression of Fibroblast Growth Factor Receptors in Human Leukemia Cells,”Cancer Research, Issue 52, pp. 2004-2007 (1992).
Bange et al. “Cancer Progression andTumor Cell Motility Are Associated with the FGFR4 Arg388Allele,”Cancer Research, Issue 62, pp. 840-847 (2002).
Batley et al., “Inhibition of FGF-1 Receptor Tyrosine Kinase Activity by PD 161570, a New Protein-tyrosine Kinase Inhibitor,”Life Sciences, vol. 62, No. 2, pp. 143-150 (1998).
Buchdunger et al., “4,5-Bis (4-flouroanilino)phthalimide: A Selective Inhibitor of the Epidermal Growth Factor Receptor Signal Transduction Pathway With Potent in Vivo Antitumor Activity,”Clin. Cancer Res., vol. 1, No. 8, pp. 813-821 (1995).
Calbiochem® Signal Transduction Catalog & Technical Resource, “Protein Tyrosine Kinase (PTK) Inhibitors”, p. 259 (1998).
Ciardello et al., “Cooperative Antiproliferative Effects of 8-Chloro-Cyclic AMP and 528 Anti-Epidermal Growth Factor Receptor Monoclonal Antibody on Human Cancer Cells,”Clin. Cancer Res., vol. 1, No. 2, pp. 161-167 (1995).
Coll-Fresno et al., “Cytotoxic activity of a diphteria toxin/FGF6 mitotoxin on human tumour cell lines,”Oncogene, Issue 14 No. 2, pp. 243-247 (1997).
Da Costa Andrade et al., “The Fibroblast grown factor receptor 4 (FGFR4) Arg388allele correlates with survival in head and neck squamous cell carcinoma,”Experimental and Molecular Pathology, vol. 82, No. 1, pp. 53-57 (2007).
Dahring et al., “Inhibition of Growth Factor-Mediated Tyrosine Phosphorylation in Vascular Smooth Muscle by PD 089828, A New Synthetic Protein Tyrosine Kinase Inhibitor,”The Journal of Pharmacology and Experimental Therapeutics, vol. 281, No. 3, pp. 1446-1456 (1997).
Dinney et al., “Therapy of Human Transitional Cell Carcinoma of the Bladder by Oral Administration of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase Inhibitor 4,5-Dianilinophthalimide,”Clin. Cancer Res., vol. 3(2), pp. 161-168 (1997).
Ensoli et al., “The Fibroblast Growth Factors”, Cytokine Handbook, 4thEdition, vol. II, Ch. 31, Angus W. Thomson and Michael T. Lotze, Ed., Academic Press (2003).
Ezzat et al., “A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells,”Biochemical and Biophysical Research Communications, vol. 287, pp. 60-65 (2001).
Friesel et al., “Spatially restricted expression of fibroblast growth factor receptor-2 duringXenopusdevelopment, ”Development, vol. 116, pp. 1051-1058 (1992).
Hamby et al., “Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine tyrosine Kinase Inhibitors,”J Med Chem, vol. 40, pp. 2296-2303 (1997).
Han et al., “Preferential Inhibition of Glioblastoma Cell With Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate,”Oncol. Res., vol. 9, pp. 581-587 (1997).
Hardcastle et al., “FGF-8 stimulates neuronal differentiation through FGFR-4a and interfers with mesoderm induction inXenopusembryos,”Current Biology, vol. 10, No. 23, pp. 1511-1514 (2002).
Hudziak et al., “p185HER2Monoclonal Antibody Has Antiproliferative Effects in Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor,”Molecular and Cellular Biology, vol. 9, No. 3, pp. 1165-1172 (1989).
Johnston et al., “bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement,”Biochem J., Issue 306, pp. 609-616 (1995).
Klint et al., “Signal transduction by fibroblast growth factor receptors,”Frontiers in Bioscience, vol. 4, pp. d165-d177 (1999).
Li et al., “Cell Transformation by Fibroblast Growth Factors Can Be Suppressed by Truncated Fibroblast Growth Factors,”Molecular and Cellular Biology, vol. 14, No. 11, pp. 7660-7669 (1994).
Mawrin et al., “Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas,”Cancer Letters, Issue 239, pp. 239-245 (2006).
McLeskey et al., “MDA-MB-134 Breast Carcinoma Cells Overexpress Fibroblast Growth Factor (FGF) Receptors and Are Growh-inhibited by FGF Ligands,”Cancer Research, Issue 54, pp. 523-530 (1994).
Mohammadi et al., “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors,”Science, Issue 276, No. 5314, pp. 955-960 (1997).
Munoz et al., “Effect of Mutation of Cytoplasmic Receptor Domain and of Genistein on Transport of Acidic Fibroblast Growth Factor into Cells,”Oncogene, 15: 525-536 (1997).
Neilson et al., “Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains,”J Bio Chem., vol. 271, No. 40, pp. 25049-25057 (1996).
Normanno et al., “Growth Inhibition of Human Colon Carcinoma Cells by Combinations of Anti-Epidermal Growth Factor-related Growth Factor Antisense Oligonucleotides,”Clin. Cancer Res., vol. 2, pp. 601-609 (1996).
Panek et al., “In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor,”The Journal of Pharmacology and Experimental Therapeutics, vol. 283, No. 3, pp. 1433-1444 (1997).
Partanen et al., “FGFR-4, a novel acidic growth factor receptor with a distinct expression pattern,”EMBO J., vol. 10, No. 6, pp. 1347-1354 (1991).
Ratisoontorn et al., “Activating (P253R, C278F) and Dominant Negative Mutations of FGFR2: Differential Effects on Calvarial Bone Cell Proliferation, Differentiation, and Mineralization,”Connective Tissue Research, vol. 44 (Suppl 1) pp. 292-297 (2003).
Rubin Grandis et al., “Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells,”Oncogene, vol. 15, No. 4, pp. 409-416 (1997).
Showalter et al., “Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, The Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases,”Pharmacol. Ther., 76 (1-3), 55-61 (1997).
Spinola et al., “Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients,”J. Clinical Oncology, vol. 23, No. 29, pp. 7307-7311 (2005).
Streit et al., “FGFR4 G388R mutation, but not FGFR4 or HER2 overexpression, correlates with survival in head and neck squamous cell carcinoma patents,”Proc of the Am Assoc for Cancer Research, vol. 43, p. 829, Abstract 4116 (2002).
Streit et al., “Involvement of he FGFR4 Arg388 Allele in Head and Neck Squamous Cell Carcinoma,”Int. J. Cancer, Issue 111, pp. 213-217 (2004).
Streit et al., “FGFR4 Arg388 Allele Correlates with Tumour Thickness and FGFR4 Protein Expres

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of diagnosing an RTK-hyperfunction induced disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of diagnosing an RTK-hyperfunction induced disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing an RTK-hyperfunction induced disorder will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4271136

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.